Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ivacaftor - Vertex Pharmaceuticals

Drug Profile

Ivacaftor - Vertex Pharmaceuticals

Alternative Names: IVA; Kalydeco; Potentiator VX-770; VRT 813077; VX-770

Latest Information Update: 05 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cystic Fibrosis Foundation Therapeutics; Vertex Pharmaceuticals
  • Developer Vertex Pharmaceuticals
  • Class Amides; Aminophenols; Quinolones; Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cystic fibrosis
  • Phase II Chronic obstructive pulmonary disease

Most Recent Events

  • 22 Oct 2019 The Spanish Government approves the reimbursement of ivacaftor in combination with ivacaftor/tezacaftor for Cystic fibrosis (In adolescents, In adults, In the elderly) in Spain
  • 21 Oct 2019 Vertex Pharmaceuticals plans to launch ivacaftor in combination with ivacaftor/tezacaftor for Cystic fibrosis (In adolescents, In adults, In the elderly) in Spain in November 2019
  • 18 Oct 2019 The CHMP of EMA adopts a positive opinion recommending expansion of usage of ivacaftor for treatment of Cystic fibrosis (In infants aged 6-12 months) with either of G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top